Fresenius SE & Co (FSNUY) AI Stock Analysis

• Market Cap: $27.77B
• Dividend Yield: 2.21%
• Average Volume (3M): 4.46K
• Price to Earnings (P/E): 61.9
• Beta (1Y): 0.23
• Revenue Growth: -19.78%
• EPS Growth: N/A
• Country: US
• Employees: 175,202
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 0.25
• Shares Outstanding: 2,252,949,200
• 10 Day Avg. Volume: 2,669
• 30 Day Avg. Volume: 4,456
• PEG Ratio: -0.52
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 3.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.13
• Price Target Upside: 15.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: $13.50 ▲(9.93%Upside)

Fresenius SE & Co's overall stock score is driven by strong earnings call performance and robust technical indicators. Financial performance is stable but needs improvement in profitability margins and revenue growth. The high valuation and absence of a dividend yield pose risks. Strategic initiatives are in place to address key challenges and enhance long-term growth.

Fresenius SE & Co Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

How the Company Makes Money

Fresenius SE & Co. generates revenue through multiple streams across its business segments. Fresenius Medical Care, the largest segment, earns income primarily by providing dialysis care and selling dialysis products such as machines and related consumables to healthcare providers. Fresenius Helios operates hospitals, earning revenue from patient care services, while Fresenius Kabi generates income through the sale of pharmaceuticals and medical devices, focusing on infusion therapies and clinical nutrition. Fresenius Vamed contributes by managing healthcare facilities and providing technical services. The company's revenue is supported by a combination of direct patient services, product sales, and healthcare infrastructure management, with strategic partnerships and acquisitions enhancing its market presence and financial performance.

Fresenius SE & Co Financial Statement Overview

Summary

Fresenius SE & Co's financial health is underscored by solid operational margins and an effective balance sheet structure, supported by strong cash flow management. However, challenges in net income margins and erratic revenue growth affect the score.

Income Statement

The income statement reveals a mixed performance. Gross profit margin for TTM (Trailing-Twelve-Months) is healthy at 24.48%, and EBIT margin is 8.65%, indicating operational efficiency. However, the net profit margin is modest at 1.91%, highlighting challenges in translating revenue into profit. Revenue growth has been erratic, with a decline in recent years, affecting overall score.

Balance Sheet

The balance sheet shows strength in equity with an equity ratio of 44.91%. The debt-to-equity ratio stands at 0.70, suggesting a balanced capital structure. However, the return on equity (ROE) is low at 2.17%, indicating limited effectiveness in generating returns on invested capital.

Cash Flow

The cash flow statement is robust, with a strong operating cash flow to net income ratio of 6.19, indicating effective conversion of income into cash. Free cash flow growth is notable, and the free cash flow to net income ratio is 3.95, highlighting efficient cash management practices. Nevertheless, recent fluctuations in free cash flow growth suggest potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.34B	21.83B	22.30B	40.84B	37.52B	36.28B
Gross Profit	10.68B	5.38B	5.06B	10.72B	10.31B	10.32B
EBITDA	5.40B	3.14B	2.73B	3.09B	6.84B	7.19B
Net Income	1.30B	471.00M	-594.00M	1.37B	1.82B	1.71B
Balance Sheet
Total Assets	64.98B	43.55B	45.28B	76.42B	71.96B	66.65B
Cash, Cash Equivalents and Short-Term Investments	1.54B	2.05B	2.56B	2.35B	2.75B	2.00B
Total Debt	26.38B	13.58B	15.83B	27.76B	27.16B	25.91B
Total Liabilities	39.16B	23.26B	25.63B	44.20B	42.67B	40.62B
Stockholders Equity	16.00B	19.54B	19.00B	20.41B	19.00B	16.95B
Cash Flow
Free Cash Flow	2.28B	1.52B	3.32B	2.28B	3.03B	4.14B
Operating Cash Flow	4.27B	2.45B	4.46B	4.20B	5.08B	6.55B
Investing Cash Flow	-2.56B	-510.00M	-3.19B	-2.61B	-2.82B	-3.01B
Financing Cash Flow	-1.39B	-2.18B	-1.38B	-1.60B	-1.45B	-3.12B

Fresenius SE & Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 12.28 is below the 20-day moving average (MA) of 12.45, above the 50-day MA of 12.13, and above the 200-day MA of 10.10, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 54.48 is Neutral, neither overbought nor oversold. The STOCH value of 76.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.

Fresenius SE & Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UHS	77 Outperform	$11.69B	10.19	18.35%	0.43%	9.73%	51.87%
FMS	77 Outperform	$16.51B	24.63	4.36%	2.80%	-0.91%	27.17%
EHC	75 Outperform	$12.03B	24.65	25.33%	0.57%	11.21%	30.38%
FSNUY	73 Outperform	$27.77B	61.86	6.23%	2.21%	-19.78%	―
THC	71 Outperform	$16.08B	11.40	38.12%	―	-1.79%	-41.85%
DVA	66 Neutral	$10.78B	14.14	260.92%	―	5.11%	14.28%
Sector *	52 Neutral	$7.45B	0.30	-61.93%	2.28%	16.62%	1.04%